Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CTSO
CTSO logo

CTSO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cytosorbents Corp (CTSO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.490
1 Day change
-1.01%
52 Week Range
1.390
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CTSO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows weak technicals, no fresh news catalyst, no meaningful analyst or insider support in the provided data, and no strong proprietary buy signal. While the options market is extremely bullish on paper, the broader evidence does not confirm a solid long-term entry. My direct view: do not buy now; wait for a better setup.

Technical Analysis

The trend is bearish to neutral. MACD histogram is negative and still contracting, RSI_6 at 46.8 is neutral, and moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5. Price closed at 0.4958, below the pivot of 0.506 and only modestly above support at 0.443, which leaves limited near-term upside unless momentum improves. The short-term pattern estimate is also weak, with only modest upside probabilities over the next day, week, and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is extremely call-heavy, with open interest put-call ratio at 0.01 and option volume put-call ratio at 0.0. That suggests very bullish speculative positioning, but the total activity is tiny and today's volume is only 1 contract, so the signal is not strong enough to outweigh the weak chart trend.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • ["Extremely bullish options positioning on the surface", "Price is near a defined support area around 0.443, which could attract traders if momentum turns", "No recent bad news in the past week"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst driving the stock", "Bearish moving average structure", "Negative MACD histogram", "Neutral RSI with no clear momentum breakout", "No strong AI Stock Picker signal", "No recent SwingMax buy signal", "No significant hedge fund accumulation", "No insider buying trend", "No recent congress trading data", "No financial snapshot was available to support a fundamental buy case"]

Financial Performance

Latest quarter financials were not available because the financial snapshot returned an error, so there is no usable quarterly growth data to support a long-term purchase decision. The latest quarter season cannot be confirmed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence here of improving Wall Street sentiment. Based on the available information, analysts appear absent from the decision set rather than supportive. Wall Street pros and cons view: pros are the very cheap share price and speculative options interest; cons are weak trend, missing fundamentals, and no visible catalyst.

Wall Street analysts forecast CTSO stock price to rise
1 Analyst Rating
Wall Street analysts forecast CTSO stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.496
sliders
Low
0.75
Averages
0.75
High
0.75
Current: 0.496
sliders
Low
0.75
Averages
0.75
High
0.75
H.C. Wainwright
Sean Lee
Neutral
downgrade
$1
AI Analysis
2025-11-14
Reason
H.C. Wainwright
Sean Lee
Price Target
$1
AI Analysis
2025-11-14
downgrade
Neutral
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on CytoSorbents to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the "continued drag" on the company's Germany revenues.

People Also Watch